Compare CURV & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURV | MXCT |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 186.7M |
| IPO Year | 2021 | 2021 |
| Metric | CURV | MXCT |
|---|---|---|
| Price | $1.12 | $1.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $1.59 | ★ $7.50 |
| AVG Volume (30 Days) | 406.5K | ★ 1.5M |
| Earning Date | 12-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,039,486,000.00 | $34,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $1.26 |
| 52 Week High | $7.19 | $5.20 |
| Indicator | CURV | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 41.45 |
| Support Level | $1.08 | $1.45 |
| Resistance Level | $1.46 | $1.80 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 10.67 | 14.42 |
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.